GLG News by Hematologists who Treat Thrombocytopenias in the U.S.

A VEGF inhibitor that appears to work well with chemo in non small cell lung carcinoma.

"New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months (p<0.001)" This is the trial that showed Erbitux + chemo prolonged survival minimally when compared to chemo alone. Now we know the ones who develop a...

Tarceva can maintain a remission in non small cell lung cancer after initial therapy with other agents. Just like Lilly's Alimta

Addition of Zevalin after a CR or PR in low grade, follicular lymphomas adds to CR rates and improves time to progression. The implication is that this will result in improved survivals.

The implication is that our new chief executive has "bigger fish to fry" than attaching drug costs??

"As part of the restructuring, the company plans to group its sales staff around specific treatment areas" including oncology, probably

Genetech is seeking FDA approval for use in the most malignant of brain tumors, Glioblastomas.

Measuring mutated K-RAS will show who will NOT respond to ImClone's Erbitux or Amgen's Vectibix. Thus to use either in CRC will not be particularly effective.

31 million more doses of Pneumovax yearly in the US??

Cell Genesys is basically stopping work on GVAX inview of failure in two trials. The cause of the failure is not readily apparent.